New and Revised Draft Q&As on Biosimilar Development andthe BPCI Act (Revision 4) Guidance for Industry
Date of Publication: 09-Mar-2026 INTELLIGENCE OVERVIEWAgency: USFDAThe U.S. Food and Drug Administration (FDA) has released Revision 4 of the draft guidance titled “New and Revised Draft Q&As on Biosimilar Development…
